This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sizemore, S. Articles by Casey, G. Search for Related Content PubMed PubMed Citation Articles by Sizemore, S. Articles by Casey, G.

Podocalyxin Increases the Aggressive Phenotype of Breast and Prostate Cancer Cells In vitro through Its Interaction with Ezrin

¹ Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio and ² School of Biomedical Sciences, Kent State University, Kent, Ohio

Requests for reprints: Graham Casey, Department of Cancer Biology/ND50, Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-445-9754; Fax: 216-445-6269; E-mail: caseyg{at}ccf.org.

Podocalyxin is an anti-adhesive transmembrane sialomucin that has been implicated in the development of more aggressive forms of breast and prostate cancer. The mechanism through which podocalyxin increases cancer aggressiveness remains poorly understood but may involve the interaction of podocalyxin with ezrin, an established mediator of metastasis. Here, we show that overexpression of podocalyxin in MCF7 breast cancer and PC3 prostate cancer cell lines increased their in vitro invasive and migratory potential and led to increased expression of matrix metalloproteases 1 and 9 (MMP1 and MMP9). Podocalyxin expression also led to an increase in mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) activity. To determine the role of ezrin in these podocalyxin-dependent phenotypic events, we first confirmed that podocalyxin formed a complex with ezrin in MCF7 and PC3 cells. Furthermore, expression of podocalyxin was associated with a changed ezrin subcellular localization and increased ezrin phosphorylation. Transient knockdown of ezrin protein abrogated MAPK and PI3K signaling as well as MMP expression and invasiveness in cancer cells overexpressing podocalyxin. These findings suggest that podocalyxin leads to increased in vitro migration and invasion, increased MMP expression, and increased activation of MAPK and PI3K activity in MCF7 and PC3 cells through its ability to form a complex with ezrin. [Cancer Res 2007;67(13):6183–91]

This article has been cited by other articles:

				J. S. Nielsen and K. M. McNagny The Role of Podocalyxin in Health and Disease J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1669 - 1676. [Abstract] [Full Text] [PDF]

				P. Sathyanarayana, E. Houde, D. Marshall, A. Volk, D. Makropoulos, C. Emerson, A. Pradeep, P. J. Bugelski, and D. M. Wojchowski CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools Blood, May 14, 2009; 113(20): 4955 - 4962. [Abstract] [Full Text] [PDF]

				R. H. Lee, M. J. Seo, A. A. Pulin, C. A. Gregory, J. Ylostalo, and D. J. Prockop The CD34-like protein PODXL and {alpha}6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice Blood, January 22, 2009; 113(4): 816 - 826. [Abstract] [Full Text] [PDF]

				H Yasuoka, M Tsujimoto, M Hirokawa, M Tori, M Nakahara, A Miyauchi, R Kodama, T Sanke, and Y Nakamura Podocalyxin expression in undifferentiated thyroid carcinomas J. Clin. Pathol., November 1, 2008; 61(11): 1228 - 1229. [Full Text] [PDF]